Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study

Tezuka, S; Ueno, M; Kobayashi, S; Hamaguchi, T; Yamachika, Y; Oishi, R; Nagashima, S; Fukushima, T; Morimoto, M; Shin, M

Tezuka, S (通讯作者),Kanagawa Canc Ctr, Dept Hepatobiliary & Pancreat Med Oncol, 2-3-2 Nakao,Asahi ku, Yokohama 2418515, Japan.

PANCREATOLOGY, 2022; 22 (6): 789